ReviewCurrent oncology (Toronto, Ont.)2026

Preclinical Rationale, Clinical Efficacy, and Safety of the Selective AKT Kinase Inhibitor Capivasertib in Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Carcinoma: A Practical Narrative Review.

Maria Rosaria Valerio et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.